Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. develops plant-derived prescription medicines for gastrointestinal disease states in people and animals. Its human-health news centers on crofelemer, including Mytesi for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and rare-disease intestinal failure programs tied to microvillus inclusion disease and short bowel syndrome through Napo Pharmaceuticals and Napo Therapeutics.
Company updates also cover animal-health products such as conditionally approved Canalevia-CA1 for chemotherapy-induced diarrhea in dogs and the Neonorm franchise for gut health in animals. Recurring corporate news includes Nasdaq listing-compliance matters, reverse stock splits, warrant exercises, stockholder meetings, proxy proposals, and other capital-structure actions.
Jaguar Health has signed a binding agreement for a $5 million non-dilutive royalty financing to support the development of crofelemer for a COVID-related indication in long-hauler patients. This financing adds to previous transactions totaling $12 million since late 2020. The company aims for accelerated conditional approval of crofelemer in the EU. The Dragon SPAC, targeting AIM Italia, will focus on Napo EU's projects, providing additional updates expected next week. Mytesi, approved by the FDA, serves as an anti-diarrheal for adults with HIV/AIDS.
Jaguar Health has launched the Napo EU website in Italy, providing resources on post-COVID-19 long-hauler syndrome, including gastrointestinal symptoms like diarrhea. The site links to relevant studies and aims to explore the conditional marketing authorization of crofelemer for inflammatory diarrhea in long-hauler patients in Europe. In a recent study, 30% of COVID-19 survivors reported ongoing symptoms, highlighting the potential market for Jaguar's Mytesi product. The company continues to advocate for its plant-based therapies targeting GI distress.
Jaguar Health (NASDAQ:JAGX) is advancing plans for an exclusive relationship with the Dragon SPAC, targeting the listing of its subsidiary, Napo EU, on AIM Italia. An MOU has been signed with Josh Mailman, the lead sponsor of Dragon SPAC, which will negotiate the merger with Napo EU. The company is also seeking conditional marketing authorization in Europe for crofelemer to treat inflammatory diarrhea, particularly among 'long-hauler' COVID-19 patients. A meeting with European regulatory authorities is scheduled for March 2021.
Jaguar Health (NASDAQ:JAGX) announced a Memorandum of Understanding (MOU) with the Dragon SPAC to enable Napo EU’s anticipated listing on AIM Italia. The focus is on seeking conditional marketing authorization for crofelemer to treat inflammatory diarrhea in long-hauler COVID-19 patients in Europe. The partnership aims to leverage Napo's experience in developing plant-based drugs, particularly crofelemer, which is currently used for noninfectious diarrhea in HIV/AIDS patients. The potential market includes 20-70 million people in Europe suffering from gastrointestinal issues related to long COVID.
Jaguar Health, Inc. (NASDAQ:JAGX) announced a webcast on January 27, 2021, at 8:30 AM ET to discuss updates on the proposed merger of its anticipated subsidiary Napo EU with a special purpose acquisition company (SPAC) focused on Post Pandemic Recovery. Jaguar is exploring conditional marketing authorization in Europe for crofelemer, aimed at addressing gastrointestinal issues in long-hauler COVID-19 patients. The webcast will feature CEO Lisa Conte and Andreea Porcelli as co-presenters.
Jaguar Health, Inc. (NASDAQ:JAGX) announced the granting of nonstatutory stock options to new employees as inducement awards. Effective December 9, 2020, one employee received options for 1,500 shares, while another received options for 35,000 shares, with an exercise price of $0.353. Additionally, on January 7, 2021, another employee was granted options for 7,000 shares at $2.68 per share. All options vest over three years, subject to continued employment. These options are part of the Company's strategy to attract and retain talent.
Jaguar Health, Inc. (NASDAQ:JAGX) announced on January 21, 2021, that it has regained compliance with Nasdaq's bid price requirement, as stated by the Nasdaq Hearings Panel on October 28, 2020. CEO Lisa Conte expressed satisfaction with this achievement, attributing it to the company's efforts since Q2 2020, such as expanding patient access to Mytesi® and securing a $6 million royalty-based capital infusion. The company is also advancing a Phase 3 clinical trial for crofelemer aimed at treating cancer therapy-related diarrhea.
Jaguar Health, Inc. (NASDAQ:JAGX) announced a webcast on January 27, 2021, at 8:30 AM ET regarding its potential merger with Post Pandemic Recovery Equity SPAC. Lisa Conte, CEO of Jaguar, and Andreea Porcelli, SPAC sponsor and CEO of Swiss Growth Forum, will co-present updates. The company aims to explore conditional marketing authorization in Europe for its product addressing gastrointestinal distress related to long COVID. Mytesi, Jaguar's FDA-approved medication, is positioned to aid patients suffering from ongoing symptoms post-COVID-19.
Jaguar Health, Inc. (NASDAQ:JAGX) announced the successful issuance of a $6 million secured promissory note to Streeterville Capital, LLC. The financing supports the development of lechlemer, aimed at treating diarrhea and dehydration in cholera patients. The investor holds a right to 18% of gross proceeds from a potential tropical disease priority review voucher (TDPRV). This program incentivizes drug development for neglected diseases and has seen previous vouchers sold for up to $350 million. Napo Pharmaceuticals, Jaguar's subsidiary, is conducting ongoing preclinical studies for lechlemer, which is derived from the Croton lechleri tree.
Jaguar Health, Inc. (NASDAQ:JAGX) has released a recap of its January 14, 2021 investor webcast and provided a replay link due to high participation. Key highlights include plans to pursue conditional marketing authorization in Europe for crofelemer, aimed at treating 'long-hauler' COVID-19 symptoms. The company announced a securities purchase agreement, raising approximately $15 million, and a $6 million agreement related to Napo's lechlemer drug candidate. Jaguar also discussed establishing Napo EU in Italy, targeting additional value from potential licensing arrangements.